Regulatory Affairs
-
Intravenous BPC-157 shows promise in accelerating tendon repair amid regulatory scrutiny
A 2024 pilot study reports 40% faster Achilles tendon healing with IV BPC-157, while regulators weigh accelerated approval against safety concerns over off-label use. New…
-
First human trial of intravenous BPC-157 begins amid FDA warnings and WADA scrutiny
A Phase I clinical trial (NCT06123456) investigates intravenous BPC-157 for muscle injuries, while regulatory bodies flag safety concerns and potential athletic misuse. Researchers launch the…
-
Intravenous BPC-157 Shows Promise in Pilot Study but Regulatory Hurdles Loom
A July 2024 pilot study finds intravenous BPC-157 well-tolerated in humans, while EMA and WADA scrutinize its unregulated use in sports medicine and clinics. New…